HRMY
Harmony Biosciences Holdings, Inc.
NASDAQ · Healthcare · Biotechnology · US
$42.25
+0.93%Aug 20, 2026, 07:18 UTC
Aurora Investment Counsel acquired a new position in Harmony Biosciences Holdings, Inc., purchasing 65,148 shares valued at approximately $2.37 million, as disclosed in a recent SEC filing.
Source:Aug 14, 2026, 14:05 UTC
Harmony Biosciences highlighted record quarterly performance for its narcolepsy treatment WAKIX and outlined development plans across its orexin, epilepsy and pitolisant lifecycle-management programs during Piper Sandler's virtual CNS Symposium.
Source:Aug 4, 2026, 11:30 UTC
Harmony Biosciences announced initial Phase 1 clinical data for its orexin-2 agonist BP-205, showing favorable pharmacokinetic and safety profiles, and plans to initiate Phase 1b and Phase 2 trials in 2026 and 2027.
Source:Aug 4, 2026, 11:30 UTC
Harmony Biosciences announced that its Pitolisant GR NDA was accepted by the FDA in July, with a target PDUFA date of April 1, 2027.
Source:Jul 16, 2026, 12:30 UTC
Harmony Biosciences preannounced record quarterly revenue of approximately $261 million for Q2 2026, representing 30% year-over-year growth, and reaffirmed full-year 2026 revenue guidance.
Jul 16, 2026, 12:30 UTC
Harmony Biosciences announced a CFO transition.
Source: